P-8880 4α-Phorbol 12-Myristate 13-Acetate, >99%

Related Terms : [4α-PMA] [4α-TPA] [4α-12-O-Tetradecanoylphorbol 13-Acetate]

  • Size
  • US $
  • £
  • ¥
  • 1 mg
  • 59
  • 54
  • 45
  • 6,600
  • Add to Cart Qty:
  • In stock
  • 5 mg
  • 239
  • 219
  • 184
  • 26,600
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 895
  • 821
  • 691
  • 99,600
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 2,970
  • 2,726
  • 2,295
  • 330,600
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 616.83
  • C36H56O8
  • [63597-44-4]

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO or ethanol. Disposal: A.

  • Negative control for studies with PMA, Cat. No. P-1680. Van Duuren, B.L. et al. "Effects of structural changes on the tumor-promoting activity of phorbol myristate acetate on mouse skin." Cancer Res. 39: 2644-2646 (1979).
  • Please request Technical Note #13 for additional information.
  • 4α-Phorbol Ester Activation of TRPV4 Channels Though long thought to be a biologically inactive or extremely weak phorbol ester analog (i. e., an ED50 >25 µM for binding to protein kinase C), 4α-PMA may prove to be a reasonably potent activator of TRPV4 channels, with utility for structure-activity studies of this phenomenon. The supposition of agonist activity for 4α-PMA on TRPV4 channels is based on the potent agonist response elicited by the very similar compound, 4α-PDD, in systems containing human VRL-2 and murine TRP12 channels [Watanabe, H., et al. "Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives." J. Biol. Chem. 277: 13569-13577 (2002)]. See the entry for 4α-PDD, Cat. No. P-2170, for an extensive description of these new and exciting results.
  • Chemical Structures. The primary structural difference between 4α-PMA and the highly potent phorbol ester-type PKC activators is the configuration at C4. In the highly active phorbol ester family, the hydroxy group at C4 is in the β configuration, i. e., rising up out of the two-dimensional structure as depicted on paper or a computer monitor. The 4-alpha-phorbol esters such as 4α-PMA, 4α-PDD and 4α-PDBu have the 4-OH group oriented down below the paper or computer screen's two-dimensional plane.
  • Nomenclature. Unless "4α" is specified, all "phorbol" compounds are automatically defined, by operation of standard chemical nomenclature conventions, as having the 4β-configuration, as part of the intrinsic meaning of the word "phorbol". This is much like the word "cholesterol", which automatically means that its hydroxy group at carbon 3 is in the β configuration; there is no need to specify "3β-cholesterol", whereas a cholesterol derivative with a 3α hydroxy group would require a "3α-cholesterol" specification. To avoid confusion in this field, it is useful to note that, technically, 4α-PMA is not a "phorbol ester", it is a "4α-phorbol ester", and the structural differences, though minor overall, are quite significant biologically. Given the extreme differences in their biological properties, both on PKC and TRPV4 channel-based phenomena, efforts to maintain distinctive names for members of these two biologically quite distinct classes of compounds appear to be well justified.
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.